Inclisiran: A Novel Agent in the Management of Hypercholesterolemia
PCSK9 is a serine protease that binds to the LDL receptors and targets the receptors for lysosomal degradation, thus reducing their recycling and decreasing the removal rate of circulating LDL-C. Monoclonal antibodies directed against PCSK9, such alirocumab and evolocumab, have been shown to cause a significant reducti...